Immunotherapies for the Effective Treatment of Primary Autoimmune Cerebellar Ataxia: a Case Series

Cerebellum. 2023 Dec;22(6):1216-1222. doi: 10.1007/s12311-022-01496-z. Epub 2022 Nov 25.

Abstract

Primary autoimmune cerebellar ataxia (PACA) is an idiopathic sporadic cerebellar ataxia that is thought to be immune-mediated but lacks biomarkers or a known cause. Here, we report two cases of immune-mediated cerebellar ataxia that responded favorably to immunotherapy, in which tissue-based indirect immunofluorescence test for serum or cerebrospinal fluid (CSF) samples yielded positive results. Case 1 was a 78-year-old man who presented with subacute progressive gait ataxia with truncal instability and dysarthria in response to steroids. Case 2 was a 62-year-old man who presented with relapses and remissions of acute progressive cerebellar ataxia occurring 1-2 times per year. Despite a favorable response to steroid treatment, he relapsed repeatedly in the absence of long-term immunosuppression. In the case of "idiopathic" cerebellar ataxia, immune-mediated causes should be investigated, and immunotherapy may have therapeutic effects.

Keywords: Cerebellar ataxia; Immunotherapy; Primary autoimmune cerebellar ataxia (PACA); Tissue-based assay (TBA).

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Autoantibodies
  • Cerebellar Ataxia* / drug therapy
  • Humans
  • Immunotherapy / methods
  • Male
  • Middle Aged
  • Spinocerebellar Degenerations*
  • Treatment Outcome

Substances

  • Autoantibodies